Unlearn.AI

[On Demand]
Search General Info
Search Education
Search Partnering Companies

Unlearn is using novel AI approaches to create disease progression models for clinical research. By leveraging disease-specific machine-learning models, Unlearn generates Digital Twins, defined as predicted placebo outcomes that are matched to actual patients in clinical trials. Incorporating Digital Twins into studies using proprietary statistical methods increases confidence, accelerates trial timelines, and enables patient level insights. Unlearn’s technology has been presented in a peer-reviewed publication in Nature, and the company is partnering with the world’s leading pharma companies. Unlearn continues to have discussions with regulators, including the FDA. The company is backed by 8VC, Alumni Ventures Group, DCVC, DCVC Bio, Eisai, Epic Ventures, and Mubadala Capital Ventures. CB Insights named Unlearn to the 2021 AI 100 List of Most Innovative Artificial Intelligence Startups and to the 2020 Digital Health 150 List of Most Innovative Digital Health Startups. Unlearn was also named People's Choice for the Biopharma track of the Pitch Perfect Startup Contest at Medcity INVEST 2021 and the winner of the Innovation Showcase at the 2020 CNS Summit. For more information, please visit www.unlearn.ai or follow @UnlearnAI on Twitter and @unlearn-ai on LinkedIn.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
Digital Twins for AD and MS
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Founder and CEO
Unlearn.AI